Ty Hanners appointed Director of Sales, US, focused on OPRA Implant System for Amputees

Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, announces that Ty Hanners has been appointed Director of Sales, US, focused on expanding the OPRA surgical system product offering to amputees. He will start on October 14, 2024.

Ty Hanners is a results-oriented sales leader with over 20 years in the prosthetic and orthopedic implant industry. He most recently served as a sales leader at Willowood Inc. and has past experience at Össur and Xtremity, innovative prosthetic and medical companies. Ty will be focused on business development, patient capture, and organizational transformation.

"We are thrilled to welcome Ty Hanners to the Integrum team. Ty's leadership and past successes will provide immediate contributions to our expanding products and commercial strategy. Ty is a results-oriented leader with a deep understanding of the industry. He has helped to develop breakthrough healthcare technologies and has experience within the O&P market," comments Jeffrey Zanni, US President, Integrum.

"I'm very impressed by the Integrum portfolio, their approved technologies, and continued innovation in improving life for amputees. I'm excited for this opportunity to manage the US Sales team and drive the success of Integrum," comments Ty Hanners, National Director of Sales, US, Integrum.

For more information, please contact Jeffrey Zanni, US President, Integrum, email jeff.zanni@integrum.se

Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.

About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.